Application of the Paris Reporting System for Urine Cytology: The Three-Year Experience of a Single Tertiary Care Institute in Thailand.

IF 1.6 4区医学 Q3 PATHOLOGY

Acta Cytologica Pub Date : 2022-01-01 Epub Date: 2022-01-07 DOI:10.1159/000521139

Bantita Phruttinarakorn, Sirithep Plumworasawat, Jitchai Kayankarnnavee, Jirasit Lualon, Atcharaporn Pongtippan

{"title":"Application of the Paris Reporting System for Urine Cytology: The Three-Year Experience of a Single Tertiary Care Institute in Thailand.","authors":"Bantita Phruttinarakorn, Sirithep Plumworasawat, Jitchai Kayankarnnavee, Jirasit Lualon, Atcharaporn Pongtippan","doi":"10.1159/000521139","DOIUrl":null,"url":null,"abstract":"Introduction: Urothelial carcinoma is one of the most common human cancers, both in Thailand and worldwide. Urine cytology is a screening tool used to detect urothelial carcinoma. The Paris System for Reporting Urinary Cytology (TPSRUC) was first published in 2016 to standardize the procedures, reporting, and management of urothelial carcinoma. Diagnostic categories include negative for high-grade urothelial carcinoma (NHGUC), atypical urothelial cells (AUCs), suspicious for HGUC (SHGUC), HGUC, low-grade urothelial neoplasm, and other malignancies.Material and methods: In a retrospective review, urine cytology specimens from 2016 to 2019 were reevaluated using the TPSRUC. The risk of high-grade malignant neoplasm (ROHM) for each diagnostic category was calculated. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of prediction of high-grade malignant neoplasms were evaluated for cases with histological follow-up specimens.Results: In total, 2,178 urine cytology specimens were evaluated, of which 456 cases had follow-up histological specimens. The ROHM in each diagnostic category was as follows: NHGUC, 17.4%; AUC, 49.9%; SHGUC, 81.2%; HGUC, 91.3%; and other malignant neoplasms, 87.5%. The sensitivity, specificity, PPV, NPV, and accuracy for high-grade malignant neoplasm prediction were 63%, 92.8%, 89%, 73.1%, and 78.5% when AUC was included as malignant in the comparison and 82.6%, 74.7%, 75.1%, 82.3%, and 78.5% when AUC was not considered malignant.Conclusions: TPSRUC provides reliable results that are reproducible by different interpreters and is a helpful tool for the detection of HGUC.","PeriodicalId":6959,"journal":{"name":"Acta Cytologica","volume":"66 2","pages":"134-141"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985032/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cytologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000521139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Introduction: Urothelial carcinoma is one of the most common human cancers, both in Thailand and worldwide. Urine cytology is a screening tool used to detect urothelial carcinoma. The Paris System for Reporting Urinary Cytology (TPSRUC) was first published in 2016 to standardize the procedures, reporting, and management of urothelial carcinoma. Diagnostic categories include negative for high-grade urothelial carcinoma (NHGUC), atypical urothelial cells (AUCs), suspicious for HGUC (SHGUC), HGUC, low-grade urothelial neoplasm, and other malignancies.

Material and methods: In a retrospective review, urine cytology specimens from 2016 to 2019 were reevaluated using the TPSRUC. The risk of high-grade malignant neoplasm (ROHM) for each diagnostic category was calculated. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of prediction of high-grade malignant neoplasms were evaluated for cases with histological follow-up specimens.

Results: In total, 2,178 urine cytology specimens were evaluated, of which 456 cases had follow-up histological specimens. The ROHM in each diagnostic category was as follows: NHGUC, 17.4%; AUC, 49.9%; SHGUC, 81.2%; HGUC, 91.3%; and other malignant neoplasms, 87.5%. The sensitivity, specificity, PPV, NPV, and accuracy for high-grade malignant neoplasm prediction were 63%, 92.8%, 89%, 73.1%, and 78.5% when AUC was included as malignant in the comparison and 82.6%, 74.7%, 75.1%, 82.3%, and 78.5% when AUC was not considered malignant.

Conclusions: TPSRUC provides reliable results that are reproducible by different interpreters and is a helpful tool for the detection of HGUC.

Abstract Image

查看原文本刊更多论文

巴黎尿液细胞学报告系统的应用:泰国一家三级医疗机构的三年经验。

导读:尿路上皮癌是最常见的人类癌症之一，无论是在泰国还是在世界范围内。尿细胞学是一种用于检测尿路上皮癌的筛查工具。巴黎尿细胞学报告系统(TPSRUC)于2016年首次发布，旨在规范尿路上皮癌的程序、报告和管理。诊断类别包括高级别尿路上皮癌(NHGUC)阴性、非典型尿路上皮细胞(AUCs)阴性、可疑的HGUC (SHGUC)、HGUC、低级别尿路上皮肿瘤和其他恶性肿瘤。材料和方法:回顾性分析2016 - 2019年尿细胞学标本，使用TPSRUC进行重新评估。计算每个诊断类别的高级别恶性肿瘤(ROHM)的风险。通过组织随访标本，对高级别恶性肿瘤的敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)及预测准确性进行评价。结果:共检查尿细胞学标本2178份，其中随访组织学标本456例。各诊断类别ROHM分别为:NHGUC, 17.4%;AUC, 49.9%;SHGUC, 81.2%;HGUC, 91.3%;其他恶性肿瘤占87.5%。高度恶性肿瘤预测的敏感性、特异性、PPV、NPV和准确性在AUC为恶性时分别为63%、92.8%、89%、73.1%和78.5%，在AUC非恶性时分别为82.6%、74.7%、75.1%、82.3%和78.5%。结论:TPSRUC检测结果可靠，可在不同的解释器中重现，是检测HGUC的有效工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Cytologica 生物-病理学

CiteScore

3.70

自引率

11.10%

发文量

审稿时长

4-8 weeks

期刊介绍： With articles offering an excellent balance between clinical cytology and cytopathology, ''Acta Cytologica'' fosters the understanding of the pathogenetic mechanisms behind cytomorphology and thus facilitates the translation of frontline research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 national cytology societies around the world, ''Acta Cytologica'' evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlations. Original papers, review articles, meta-analyses, novel insights from clinical practice, and letters to the editor cover topics from diagnostic cytopathology, gynecologic and non-gynecologic cytopathology to fine needle aspiration, molecular techniques and their diagnostic applications. As the perfect reference for practical use, ''Acta Cytologica'' addresses a multidisciplinary audience practicing clinical cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine.